NEUROCRINE Aktie

 

Neurocrine Biosciences earns Bull of the Day on rising earnings forecasts, while Ryanair is Bear of the Day as weaker fares and cost pressures weigh on outlook....

Neurocrine Biosciences (NBIX) has quietly become one of biotech's strongest earnings stories....

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes....

Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deoxycorticosterone Nearly all patients (14/15) reduced their total glucocorticoid dose with......

WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) on Monday reported positive two-year data from its Phase 3 CAHtalyst Pediatric study of Crenessity in children and adolescents with classi......

Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITY Cross-sectional caregiver survey data showed universal satisfaction with CRENESSITY, willingness to recommend......

Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among participants who were overweight or obese at baseline, 37% achieved >5% reduction in body......

Sherwin, Stephen A. - Aufsichtsrat - Tag der Transaktion: 2026-06-05...

Norwalk, Leslie V. - Aufsichtsrat - Tag der Transaktion: 2026-06-04...

New 48-week KINECT® 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Abnormal Involuntary Movement Scale total score); INGREZZA is the only vesicular monoamine......

Nearly all individuals with intellectual and developmental disabilities experienced improvement in tardive dyskinesia severity after starting INGREZZA, and of those, 89% experienced improvement within 4 weeks Clinician-reported data showed improvements in key aspects of daily life......

Cooke, Julie - Vorstand - Tag der Transaktion: 2026-06-02...

Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care continuum New data demonstrate the effect of CRENESSITY on long-term androgen control and......

Onyia, Jude - Vorstand - Tag der Transaktion: 2026-06-01...

Delaet, Ingrid - Vorstand - Tag der Transaktion: 2026-05-29...

Onyia, Jude - Vorstand - Tag der Transaktion: 2026-05-27...

Boyer, David W. - Vorstand - Tag der Transaktion: 2026-05-26...

SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: William Blair 46th Annual Growth Stock Conference. Fireside chat on Tuesday, June 2, 2026 at 10:40 AM CT (11:40......

Gorman, Kevin Charles - Aufsichtsrat - Tag der Transaktion: 2026-05-19...

Dr. Angelov brings extensive industry experience across multiple therapeutic areasSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. "We are pleased to welcome Dr. Angelov to the Vistagen team,” said President and Chief Executive Officer of Vistagen, Shawn Singh. “His two decades of leadership across clinical development and medical affairs, including roles at Karuna, Neurocrine, Novartis, and Teva, will be instrumental as we work to improve suboptimal standards of care in our targeted therapeutic areas.” Dr. Angelov most recently served as CMO at Theranica, a neuromodulation therapeutics company. Previously, Dr. Angelov served as Managing Director at ANG Holding, a...